The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 8 to 5 that the available data in support of approving of Natpara® for the long-term treatment of Hypoparathyroidism.
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 8 to 5 that the available data in support of approving of Natpara® for the long-term treatment of Hypoparathyroidism, a rare endocrine disorder characterized by insufficient levels of parathyroid hormone (PTH).
Natpara is a bioengineered replacement therapy for endogenous PTH developed by NPS Pharma. The FDA in addition to the European Medicines Agency has granted orphan drug status for Natpara for the treatment of Hypoparathyroidism. In the EU, the trade name for this drug is Natpar™.
EMDAC reviewed data from the Natpara clinical development program for Hypoparathyroidism, which consisted of one pharmacology study and four efficacy and safety studies. REPLACE, the pivotal Phase 3 study, was a randomized, double-blind, placebo controlled study and the largest clinical trial conducted to date in Hypoparathyroidism.
Francois Nader, MD, president and chief executive officer of NPS Pharma stated “We look forward to working with the FDA to complete the final stages of review of our BLA for Natpara.”
The Committee’s recommendation will be considered by the FDA in its review of the company’s Biologics License Application (BLA) for Natpara, which has a Prescription Drug User Fee Act (PDUFA) date of October 24, 2014. The FDA is is not obligated to follow its committee’s recommendation; however it normally does.
ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComs per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact email@example.com.
Do you have an upcoming Advisory Committee Meeting?
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us